Research News
View articles by month and year
-
Another Study Shows Ten Years of Tamoxifen Better Than Five for Early-Stage, Estrogen-Receptor-Positive Disease
Another large study finds 10 years of tamoxifen are better than 5.
-
SERM Hormonal Therapy Medicines Help Reduce Risk in Women at High Risk, But Aren’t Widely Used
A new study underscores the effectiveness of SERM hormonal therapy medicines to reduce breast cancer risk, but also found that they aren’t widely used because of concerns about side effects.
-
Study Suggests Lack of Vitamin D Production During Winter Months May Make Tamoxifen Less Effective
A study by Canadian researchers suggests that lower vitamin D levels during winter months may interfere with tamoxifen’s effectiveness.
-
High-Risk Women Often Don’t Take Risk-Reducing Medicines Because of Side Effects
A report written for the U.S. Preventive Services Task Force says that many women at high risk of breast cancer don’t take medicines that can lower that risk because of side effects.
-
About 25% of Women Either Don’t Start or Don’t Finish Hormonal Therapy
A study suggests that about 25% of women who are prescribed hormonal therapy to reduce the risk of recurrence after surgery either don’t start taking the medicine or stop taking it early.
-
Femara Better Than Tamoxifen for Certain Types of Breast Cancer
Femara was better than tamoxifen in treating postmenopausal women diagnosed with estrogen-receptor-positive, HER2-negative, lobular breast cancer; it was also better at treating luminal B breast cancers.
-
Experimental Medicine Seems to Help Treat Estrogen-Receptor-Positive, HER2-Negative, Advanced-Stage Breast Cancer
An early study suggests that an experimental medicine given in combination with Femara offers more benefits in treating advanced-stage, estrogen-receptor-positive, HER2-negative breast cancer than Femara alone.
-
Higher Faslodex Dose Better for Recurrent or Metastatic Breast Cancer
A study has found that women diagnosed with recurrent or metastatic, hormone-receptor-positive breast cancer lived longer when they got 500 mg of Faslodex compared to women who got 250 mg of Faslodex.
-
Ten Years of Tamoxifen Better Than Five for Early-Stage, Estrogen-Receptor-Positive Disease
For women diagnosed with early-stage, estrogen-receptor-positive breast cancer, 10 years of tamoxifen offers more benefits than 5 years.
-
Fareston Is Effective Against Some Advanced-Stage Cancers That Have Stopped Responding to Aromatase Inhibitors
A small study has found that Fareston is a good treatment option for postmenopausal women diagnosed with advanced-stage hormone-receptor-positive breast cancer that grew while being treated with the aromatase inhibitors Arimidex or Femara.
